Hims & Hers Health, Inc. $HIMS Shares Sold by Sanctuary Advisors LLC

Sanctuary Advisors LLC decreased its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 18.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 104,678 shares of the company’s stock after selling 23,438 shares during the quarter. Sanctuary Advisors LLC’s holdings in Hims & Hers Health were worth $2,173,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in HIMS. Sigma Planning Corp lifted its position in shares of Hims & Hers Health by 1.5% during the 1st quarter. Sigma Planning Corp now owns 26,007 shares of the company’s stock valued at $540,000 after acquiring an additional 388 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Hims & Hers Health in the 1st quarter worth $354,000. State of Michigan Retirement System raised its position in shares of Hims & Hers Health by 13.7% during the first quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company’s stock worth $48,549,000 after purchasing an additional 280,900 shares during the period. Principal Financial Group Inc. raised its position in shares of Hims & Hers Health by 97.3% during the first quarter. Principal Financial Group Inc. now owns 1,282,266 shares of the company’s stock worth $26,620,000 after purchasing an additional 632,282 shares during the period. Finally, Fifth Third Bancorp raised its position in shares of Hims & Hers Health by 3,584.8% during the first quarter. Fifth Third Bancorp now owns 82,171 shares of the company’s stock worth $1,706,000 after purchasing an additional 79,941 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Up 0.3%

HIMS stock opened at $32.79 on Wednesday. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The company has a market cap of $7.59 billion, a price-to-earnings ratio of -364.36, a PEG ratio of 92.03 and a beta of 2.35. The company has a 50 day moving average of $30.37 and a two-hundred day moving average of $26.34.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The company had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company’s revenue was up 3.8% compared to the same quarter last year. During the same period last year, the company posted $0.20 earnings per share. On average, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.03 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In other news, Director David B. Wells acquired 48,400 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were purchased at an average price of $24.23 per share, for a total transaction of $1,172,732.00. Following the completion of the acquisition, the director owned 224,417 shares of the company’s stock, valued at approximately $5,437,623.91. This represents a 27.50% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Irene Becklund sold 4,490 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $141,435.00. Following the transaction, the insider directly owned 6,790 shares in the company, valued at approximately $213,885. The trade was a 39.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 83,126 shares of company stock worth $2,711,339. 11.76% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of recent analyst reports. UBS Group set a $23.00 price target on Hims & Hers Health in a research report on Friday, May 22nd. Jefferies Financial Group set a $24.50 price objective on Hims & Hers Health in a report on Tuesday, May 12th. Wall Street Zen lowered shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $25.00 target price on shares of Hims & Hers Health in a report on Tuesday, May 5th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $30.70.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.